Radiofrequency ablation for benign or indeterminate thyroid nodules and low‑risk papillary thyroid cancer
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
M.D. Anderson Cancer Center · NCT07140757
This project sees if radiofrequency ablation shrinks benign or indeterminate thyroid nodules and controls low‑risk papillary thyroid cancer in adults, and how the treatment affects patients' quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT07140757 on ClinicalTrials.gov |
What this trial studies
This is an observational registry that follows adults treated with ultrasound‑guided radiofrequency ablation (RFA) as part of their clinical care. The primary measure is change in thyroid nodule volume over time after RFA. Secondary data include patient‑reported health‑related quality of life via questionnaires, serial sonographic features of nodules, and rates of adverse events. Participants are adults scheduled for RFA at MD Anderson who are not surgical candidates or who decline surgery, and follow‑up occurs at that center.
Who should consider this trial
Good fit: Adults (age ≥18) scheduled for ultrasound‑guided RFA for biopsy‑proven benign or indeterminate thyroid nodules, low‑risk papillary thyroid carcinoma without metastasis, or small local recurrence who are not surgical candidates or who decline surgery.
Not a fit: Patients with metastatic or higher‑risk thyroid cancer, or those judged unsuitable for RFA by their treating physician, are unlikely to benefit from the approaches tracked in this project.
Why it matters
Potential benefit: If successful, the results could support RFA as a less‑invasive option that reduces nodule size, may avoid surgery for some patients, and provides data on quality‑of‑life outcomes.
How similar studies have performed: Previous observational and interventional work has shown RFA reliably reduces the volume of benign thyroid nodules and early reports suggest promise for selected low‑risk papillary cancers, though long‑term cancer control data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria 1. Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC 2. Participant is over 18 years and is either not a surgical candidate or has declined surgery. 3. Capable and willing to provide written informed consent 4. Participant has one of the following diagnoses: * Biopsy-proven benign thyroid nodules causing compressive and/or cosmetic symptoms who are requesting treatment, * Biopsy-proven indeterminate nodules (AUS or follicular neoplasm) * Papillary thyroid carcinoma (PTC) without metastasis * Locally recurrent thyroid cancer (\< 2 cm). Exclusion Criteria 1. Participants meeting any of the following criteria will be excluded: 2. Participants considered unsuitable for RFA by the treating physician
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Study coordinator: Victoria E Banuchi, MD
- Email: vebanuchi@mdanderson.org
- Phone: 346-217-8668
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Low Risk, Papillary Thyroid Cancer, Radiofrequency Ablation